Avicanna AI Stock Analysis
Avicanna (AVCNF) AI Stock Analysis
Avicanna
(Other OTC:AVCNF)
No summary available
Avicanna (AVCNF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $8.08M
- Dividend Yield
- ―
- Average Volume (3M)
- 84.89K
- Price to Earnings (P/E)
- -2.6
- Beta (1Y)
- 1.42
- Revenue Growth
- 0.74%
- EPS Growth
- -139.80%
- Country
- US
- Employees
- 112
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Avicanna Business Overview & Revenue Model
Company Description
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health ma...
Avicanna Earnings Call Summary
The call emphasized material operational and scientific progress—improved gross margins (53%, +10 pts), reduced operating expenses (–9%), stronger liquidity (working capital +23%), R&D/IP milestones (PwdRX/data and new USPTO patent), and clinical advancements (450 patient RWE study published; Phase II underway). These positives were tempered by flat top-line revenue at $25.5M, a still-negative full-year adjusted EBITDA (–$300k) and net loss ($2.7M), early-stage commercial launches (soft launch of Trunerox) and ongoing regulatory and market uncertainties (U.S. rescheduling dependency and stock overhang). On balance, the company presented clear momentum on margins, efficiency, IP and clinical programs while acknowledging remaining commercialization and market-risk headwinds.
Q4-2025 Updates
Positive Updates
Negative Updates
Company Guidance
Guidance for 2026 targets continued profitable, capital-light scaling: management plans to internationalize RHO Phyto and roll out 3.0 fast-acting products while leveraging two new delivery platforms finalized in 2025 (in fluid and PwdRX — PwdRX showed a 74% increase in bioavailability, 63% higher peak plasma concentration and 134% higher peak concentration versus MCT oil in vitro). Key numeric goals and context: 2025 revenue was $25.5M (MyMedi $20.4M), gross profit $13.5M (53% margin, +10% vs 2024), adjusted EBITDA loss improved to $300k (71% improvement vs a $1.0M loss in 2024) with Q4 adjusted EBITDA positive $310k, net loss down 41% to $2.7M, working capital +23%, only $1.0M raised in 2025 (vs $4.8M in 2024), no debt, 50 Canadian SKUs with 170 listings ( listings +26% YoY), presence in 24 markets and a planned Australia launch (6th continent), continued RWE (≈450 patients) and active Phase I/II trials, plus scaling exports from Aureus (international revenue ~$1.9M) and pursuit of a U.S. senior-exchange listing.
Avicanna Peers Comparison
Overall Rating
TSE:INNO54Neutral
TSE:LABS54Neutral
TSE:CWEB42Neutral
TSE:PCLO42Neutral
TSE:CRDL41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:INNO | 54Neutral | CAD 8.19M | -6.15 | -19.37% | ― | -19.20% | 42.54% |
| TSE:LABS | 54Neutral | CAD 25.63M | -5.60 | -13.79% | ― | -6.74% | 43.54% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:CWEB | 42Neutral | CAD 65.11M | -0.85 | -285.96% | ― | -7.77% | -52.56% |
| TSE:PCLO | 42Neutral | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% |
| TSE:CRDL | 41Neutral | CAD 173.75M | -4.24 | -180.13% | ― | ― | 29.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AVCNF | Avicanna Inc | 0.06 | -0.13 | -67.91% | |
| TSE:CWEB | Charlotte's Web Holdings (OTC) | 0.26 | 0.14 | 112.50% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | -0.01 | -7.14% | |
| TSE:PCLO | Pharmacielo | 0.05 | 0.01 | 11.11% | |
| TSE:CRDL | Cardiol Therapeutics Inc. | 1.46 | -0.01 | -0.68% | |
| TSE:INNO | Innocan Pharma Corporation | 1.82 | -14.18 | -88.63% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.